Arterial Thrombosis Pipeline Guide, H1 2020 - Therapeutics Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type
DUBLIN, April 22, 2020 /PRNewswire/ -- The "Arterial Thrombosis - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This Pharmaceutical and Healthcare pipeline guide provides comprehensive information on the therapeutics under development for Arterial Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Arterial Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Arterial Thrombosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Report Scope
-- The pipeline guide provides a snapshot of the global therapeutic
landscape of Arterial Thrombosis (Cardiovascular).
-- The pipeline guide reviews pipeline therapeutics for Arterial Thrombosis
(Cardiovascular) by companies and universities/research institutes based
on information derived from company and industry-specific sources.
-- The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages.
-- The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing and
collaboration details, R&D brief, MoA & other developmental activities.
-- The pipeline guide reviews key companies involved in Arterial Thrombosis
(Cardiovascular) therapeutics and enlists all their major and minor
projects.
-- The pipeline guide evaluates Arterial Thrombosis (Cardiovascular)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
-- The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-- The pipeline guide reviews latest news related to pipeline therapeutics
for Arterial Thrombosis (Cardiovascular).
Reasons to Buy
-- Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-- Recognize emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage.
-- Find and recognize significant and varied types of therapeutics under
development for Arterial Thrombosis (Cardiovascular).
-- Classify potential new clients or partners in the target demographic.
-- Develop tactical initiatives by understanding the focus areas of leading
companies.
-- Plan mergers and acquisitions meritoriously by identifying key players
and it's most promising pipeline therapeutics.
-- Formulate corrective measures for pipeline projects by understanding
Arterial Thrombosis (Cardiovascular) pipeline depth and focus of
Indication therapeutics.
-- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-- Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Companies Mentioned
-- Anthos Therapeutics Inc
-- Astellas Pharma Inc
-- Bristol-Myers Squibb Co
-- GLSynthesis Inc
-- Jiangsu Hengrui Medicine Co Ltd
-- Johnson & Johnson
-- MDI Therapeutics Inc
-- Oasis Pharmaceuticals LLC
-- Thromboserin Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8itpt1
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
